new: "Machine learning models for hydrogen bond donor and acceptor strengths using large and diverse training data generated by first-principles interaction free energies" jcheminf.biomedcentral.com/articles/10.11…

After a long deliberation the judges arrived at a unanimous winner of our $250k startup pitch competition. Congrats to Paradox Immunotherapeutics!!

This could be the future of shrooms and other psychedelics. bit.ly/2WS7vvR

ATAI Life Sciences and Cyclica launch Entheogenix Biosciences Inc., a JV that will revolutionize drug development for mental health disorders by designing new compounds inspired by desirable psychedelics properties. businesswire.com/news/home/2019… #mentalhealth #medicines #depression

With Mitacs support, Cyclica has partnered with Bo Wang of University of Toronto to examine the viability of existing drugs as treatment for #COVID19. They will apply #AI to mine biological networks formed between virus & human proteins & predict drugs that can interrupt these interactions.

Thanks for the kind support from Mitacs and partnership from Cyclica. We aim to utilize #AI to expedite the drug repurposing discovery for #COVID19. Please DM if you are passionate about #AI and #drugdiscovery. Position available Vector Institute Peter Munk Cardiac Centre UHN Research

As part of our AlphaFold series, our third post explores the breakdown of proteome coverage by protein class authored by Stephen MacKinnon & David Kuter. Link to the post: lnkd.in/eNpdnv9y #AlphaFold #artificialintelliegence #drugdiscovery #MachineLearning

Thanks to Dene Moore & The Globe and Mail for featuring us, Andreas Windemuth, Stephen MacKinnon, & our recent collaborator Cleber Trujillo from @VyantBio. #drugdiscovery #artificialintelligence #MachineLearning

Have a quick 👀 Stephen MacKinnon's newest post, where he discusses how #SAMR is similar to the role that @DeepMind 's #AlphaFold plays in Drug Discovery. 👉blog.cyclicarx.com/recognizing-tr…